NCT03409263 (AUTIPS) is a clinical trial of Observational study in Portal Hypertension, sponsored by Thomas Reiberger.

Who is sponsoring NCT03409263?

NCT03409263 is sponsored by Thomas Reiberger.

What drugs are being tested in NCT03409263?

Interventions in NCT03409263: Observational study.

What condition does NCT03409263 study?

NCT03409263 studies Portal Hypertension.

Is NCT03409263 still recruiting?

NCT03409263 is currently recruiting now. Last updated 6 November 2024.

Last reviewed 2024-11-06 · How we verify

NCT03409263: AUTIPS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Austrian Registry on Transjugular Intrahepatic Portosystemic Shunts

Recruiting now Last updated 6 November 2024

What this trial tests

trial testing Observational study in Portal Hypertension in 400 participants. Currently enrolling.

Timeline

28 March 2018

Primary endpoint
31 December 2027

31 December 2027

Quick facts

Lead sponsor	Thomas Reiberger
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	400
Start date	28 March 2018
Primary completion	31 December 2027
Estimated completion	31 December 2027
Sites	1 location across Austria

Drugs / interventions tested

Observational study — full drug profile →

Conditions studied

Portal Hypertension — all drugs for Portal Hypertension →

Sponsor

Thomas Reiberger

Who can join

Adults 18 to 99, any sex, with Portal Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with TIPS will be recruited in this prospective registry study. The clinical course will be documented and biomarkers for prediction of complicatiosn will be assessed.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites.
Thaler J, Lisman T, Quehenberger P, Hell L, et al · · 2022 · cited 14× · PMID 34020489 · DOI 10.1055/a-1515-9529
Decreasing interleukin-6 levels after TIPS predict outcomes in decompensated cirrhosis.
Kornfehl A, Tiede A, Hemetsberger P, Kappel J, et al · · 2025 · cited 13× · PMID 40124165 · DOI 10.1016/j.jhepr.2024.101308
Alcohol Use After TIPS Implantation Significantly Increases the Risk of ACLF and Liver-Related Death.
Schwarz C, Kornfehl A, Abid R, Müllner-Bucsics T, et al · · 2026 · cited 2× · PMID 41288402 · DOI 10.1002/ueg2.70131
Effectiveness of controlled-expansion transjugular intrahepatic portosystemic shunt (CX-TIPS) in an interdisciplinary setting at a large tertiary center.
Hintersteininger M, Kappel J, Müllner-Buscics T, Riegler S, et al · · 2026 · cited 2× · PMID 40905971 · DOI 10.1007/s00508-025-02606-7
Research Communication: The Cumulated Spontaneous Portosystemic Shunts (SPSS) Area Decreases After TIPS and Impacts on Prognosis.
Hintersteininger M, Müllner-Bucsics T, Riegler S, Dominik N, et al · · 2026 · PMID 40990070 · DOI 10.1111/apt.70381
UEG Week 2024 Moderated Posters
· 2024

Verify or expand the search:

Other trials of Observational study

Trials testing the same drug.

NCT07255443 — Intestinal Colonization With Carbapenem Resistant Enterobacteriaceae Among ICU Patients at Assiut University Hospital · not yet recruiting
NCT07343713 — Correlation Between the Degree of Middle Ear Pressure and the Eustachian Tube Dimensions : Radiological Study · not yet recruiting
NCT07192991 — Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America · not yet recruiting
NCT07219927 — Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: · recruiting
NCT06244238 — A Study on the Relationship Between Job Satisfaction and Retention Intentions of Emergency Room Nurses · unknown

Other recruiting trials for Portal Hypertension

Currently open trials in the same condition.

NCT07439939 — Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Place · recruiting
NCT07521332 — Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis · Phase 4 · recruiting
NCT07419724 — Construction of a Portal Hypertension Biobank · recruiting
NCT07116096 — Effect of Handgrip Strength on Portal Vein Hemodynamics in Patients With Liver Cirrhosis · NA · recruiting
NCT07080697 — A Study to Evaluate Splenectomy on Debridement for Acute Necrotizing Pancreatitis With Pancreatic Sinistral Portal Hyper · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03409263 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Thomas Reiberger
Last refreshed: 6 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03409263.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing